Contrasting Foamix Pharmaceuticals (FOMX) & ImmuDyne (IMMD)
Foamix Pharmaceuticals (NASDAQ:FOMX) and ImmuDyne (OTCMKTS:IMMD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.
This is a summary of recent ratings for Foamix Pharmaceuticals and ImmuDyne, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insider and Institutional Ownership
62.6% of Foamix Pharmaceuticals shares are owned by institutional investors. 3.3% of Foamix Pharmaceuticals shares are owned by company insiders. Comparatively, 31.0% of ImmuDyne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Foamix Pharmaceuticals and ImmuDyne’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Foamix Pharmaceuticals and ImmuDyne’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Foamix Pharmaceuticals||$3.67 million||51.77||-$65.71 million||($1.76)||-1.99|
ImmuDyne has lower revenue, but higher earnings than Foamix Pharmaceuticals.
ImmuDyne beats Foamix Pharmaceuticals on 4 of the 7 factors compared between the two stocks.
Foamix Pharmaceuticals Company Profile
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus. The company is also developing FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel.
ImmuDyne Company Profile
Immudyne, Inc., an Internet based direct response marketing company, manufactures and sells personal care and nutritional supplement products. Its products portfolio include Shapiro MD, a shampoo, conditioner, and leave-in foamer for men and women; and iNR Wellness, a daily nutritional supplement that contains yeast, oat, and mushroom beta glucans. The company sells its products worldwide through technology infrastructure and relationships with agencies, third party marketers, and online advertising platforms, as well as through its Websites inrwellness.com and shapiromd.com. The company was formerly known as Anina Resources, Inc. Immudyne, Inc. was incorporated in 1987 and is based in New York, New York.
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.